HRP20130941T1 - Citratna sol 9e-15-(2-pirolidin-1-iletoksi)-7,12,25-trioksa-19,21,24-triazatetraciklo[18.3.1.1(2,5).1(14,18)]heksakoza-1(24),2,4,9,14,16,18(26),20,22-nonaena - Google Patents

Citratna sol 9e-15-(2-pirolidin-1-iletoksi)-7,12,25-trioksa-19,21,24-triazatetraciklo[18.3.1.1(2,5).1(14,18)]heksakoza-1(24),2,4,9,14,16,18(26),20,22-nonaena Download PDF

Info

Publication number
HRP20130941T1
HRP20130941T1 HRP20130941AT HRP20130941T HRP20130941T1 HR P20130941 T1 HRP20130941 T1 HR P20130941T1 HR P20130941A T HRP20130941A T HR P20130941AT HR P20130941 T HRP20130941 T HR P20130941T HR P20130941 T1 HRP20130941 T1 HR P20130941T1
Authority
HR
Croatia
Prior art keywords
salt
scale
ray diffraction
salt according
triazatetracyclo
Prior art date
Application number
HRP20130941AT
Other languages
English (en)
Croatian (hr)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cell Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics, Inc. filed Critical Cell Therapeutics, Inc.
Publication of HRP20130941T1 publication Critical patent/HRP20130941T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20130941AT 2009-07-15 2010-07-14 Citratna sol 9e-15-(2-pirolidin-1-iletoksi)-7,12,25-trioksa-19,21,24-triazatetraciklo[18.3.1.1(2,5).1(14,18)]heksakoza-1(24),2,4,9,14,16,18(26),20,22-nonaena HRP20130941T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (1)

Publication Number Publication Date
HRP20130941T1 true HRP20130941T1 (hr) 2013-11-08

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130941AT HRP20130941T1 (hr) 2009-07-15 2010-07-14 Citratna sol 9e-15-(2-pirolidin-1-iletoksi)-7,12,25-trioksa-19,21,24-triazatetraciklo[18.3.1.1(2,5).1(14,18)]heksakoza-1(24),2,4,9,14,16,18(26),20,22-nonaena

Country Status (18)

Country Link
US (1) US9062074B2 (enExample)
EP (1) EP2454266B1 (enExample)
JP (2) JP6013911B2 (enExample)
CN (1) CN102762577B (enExample)
AR (2) AR077483A1 (enExample)
BR (1) BR112012000750B1 (enExample)
CA (1) CA2768210C (enExample)
DK (1) DK2454266T3 (enExample)
ES (1) ES2429525T3 (enExample)
HR (1) HRP20130941T1 (enExample)
MX (1) MX2012000680A (enExample)
PL (1) PL2454266T3 (enExample)
PT (1) PT2454266E (enExample)
RU (1) RU2543721C2 (enExample)
SI (1) SI2454266T1 (enExample)
SM (1) SMT201300112B (enExample)
TW (1) TWI537276B (enExample)
WO (1) WO2011008172A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
ES2506040T3 (es) * 2005-11-16 2014-10-13 Cti Biopharma Corp. Derivados de pirimidina ligados a oxígeno

Also Published As

Publication number Publication date
CN102762577B (zh) 2015-01-07
AR077483A1 (es) 2011-08-31
MX2012000680A (es) 2012-02-28
HK1178159A1 (en) 2013-09-06
TW201107336A (en) 2011-03-01
PT2454266E (pt) 2013-10-10
US20120196876A1 (en) 2012-08-02
BR112012000750B1 (pt) 2021-05-25
JP6013911B2 (ja) 2016-10-25
RU2543721C2 (ru) 2015-03-10
CA2768210A1 (en) 2011-01-20
SI2454266T1 (sl) 2013-10-30
AR114987A2 (es) 2020-11-11
EP2454266B1 (en) 2013-07-10
ES2429525T3 (es) 2013-11-15
DK2454266T3 (da) 2013-09-08
SMT201300112B (it) 2013-11-08
JP2012533539A (ja) 2012-12-27
CN102762577A (zh) 2012-10-31
JP2015164941A (ja) 2015-09-17
WO2011008172A1 (en) 2011-01-20
US9062074B2 (en) 2015-06-23
CA2768210C (en) 2017-08-15
RU2012105044A (ru) 2013-08-20
PL2454266T3 (pl) 2014-01-31
BR112012000750A8 (pt) 2018-02-06
TWI537276B (zh) 2016-06-11
EP2454266A1 (en) 2012-05-23
BR112012000750A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
HRP20151324T1 (hr) Soli nilotiniba i njihovi kristalni oblici
HRP20121028T1 (hr) Kristalni oblici febuksostata
TWI562991B (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
IL226392A (en) An emotion for acquiring physiological signals
HRP20150771T1 (hr) Spoj za inhibiciju notch signalnog puta
AP2012006189A0 (en) 2'-fluoro substituted carbanucleoside analogs for antiviral treatment.
ME02805B (me) Inhibitori cdc7
IL217566A (en) Extended detection capability in low contrast for radiographic imaging systems
FR2958291B1 (fr) Procede de preparation de derives d'amino-benzofurane
ZA200904745B (en) Spirocyclic tetronic acid derivatives
FR2962731B1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
PT2744802T (pt) Compostos para ligação às glicoproteínas iib/iiia específicas de plaquetas e a sua utilização em imagiologia de trombos
SG175066A1 (en) 6'-sialyllactose salts and process for their synthesis and for the synthesis of other a-sialyloligosaccharides
FR3002733B1 (fr) Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2923484B1 (fr) Procede de preparation de composes morphiniques
EP2220103A4 (en) NOVEL MANGIFERIN CALCIUM SALTS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
FR2940968B1 (fr) Procede de preparation de composes fluores olefiniques
FR2947265B1 (fr) Procede de preparation d'alkylalcanolamines
FR2948360B1 (fr) Procede de preparation de composes fluores olefiniques
EP2655364A4 (en) PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS DITOSYLATE SALT
FR2935701B1 (fr) Procede de preparation de composes fluores olefiniques
IL223752A0 (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical preparations containing it
FR2946338B1 (fr) Procede de preparation de composes fluores olefiniques
PL2809329T3 (pl) Skrobia hydroksyalkilowa w połączeniu z cytostatykiem do leczenia raków poprzez zmniejszenie szybkości wzrostu guza
BR112012000750A2 (pt) "sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno"